![conference banner](/images/conference-banner.jpeg)
Abstract
Aims: To investigate the short-term objective response and treatment toxicity of anlotinib as a combination treatment in patients with Recurrent or Metastatic Nasopharyngeal Carcinoma (RM-NPC).
Methods: Patients with RM-NPC who received anlotinib as a combination treatment between March 2021 and July 2022 were retrospectively analyzed.The efficacy and safety of anlotinib as a combination treatment were analyzed.
Results: A total of 17 patients with RM-NPC were included in this study. Of these patients, 2 (11.8%) had local recurrence, 4 (23.5%) had cervical lymph node recurrence, and 11 (64.9%) had distant failure. The most common metastatic site was the liver (47.1%), followed by the lung (23.5%) and bone (23.5%). Anlotinib was given as first-line treatment in 3 patients (17.6%), second lines treatment in 7 patients (41.2%), and third to six-lines treatment in 7 patients (41.2%). All patients received anlotinib combined with chemotherapy and/or immunotherapy. One patient achieved a complete response (5.9%), 7 patients had a partial response (41.2%), 5 patients had stable disease (29.4%), and 4 patients had progressive disease (23.5%). The overall disease control rate and the overall response rate were 76.5% and 47.1%, respectively. The median progression-free survival was 8.1 months, and the median overall survival was not reached. The incidence of grade 3 adverse events was 30%. No unexpected side effects or treatment-related death were observed.
Conclusion: Anlotinib, as a combination treatment, has a promising antitumor activity and a manageable safety profile in patients with RM-NPC. Our results add to the growing evidence that supports the benefits of combining antiangiogenic drugs in RM-NPC. Randomized controlled clinical trials investigating the evaluation of anlotinib are warranted.
Keywords: Nasopharyngeal carcinoma, anlotinib, chemotherapy, efficacy, safety, immunotherapy.
[http://dx.doi.org/10.1016/S0140-6736(19)30956-0] [PMID: 31178151]
[http://dx.doi.org/10.1093/annonc/mds266] [PMID: 22997460]
[http://dx.doi.org/10.1200/JCO.2015.60.9347] [PMID: 26351355]
[http://dx.doi.org/10.1016/j.ctrv.2019.101890] [PMID: 31470314]
[http://dx.doi.org/10.1016/S1470-2045(21)00302-8] [PMID: 34174189]
[http://dx.doi.org/10.1200/JCO.20.02712] [PMID: 33492986]
[http://dx.doi.org/10.1038/bjc.2017.357] [PMID: 29065104]
[http://dx.doi.org/10.1200/JCO.21.00396] [PMID: 34379443]
[http://dx.doi.org/10.1200/JCO.2017.77.0388] [PMID: 29584545]
[http://dx.doi.org/10.1158/1078-0432.CCR-17-1667] [PMID: 29301831]
[http://dx.doi.org/10.1080/14728222.2020.1751820] [PMID: 32249657]
[http://dx.doi.org/10.1080/02286203.2022.2155601]
[http://dx.doi.org/10.1016/j.matcom.2021.12.004]
[http://dx.doi.org/10.1016/j.rinp.2022.105963]
[http://dx.doi.org/10.3934/math.2021669]
[http://dx.doi.org/10.1038/nrc3627] [PMID: 24263190]
[http://dx.doi.org/10.1016/S1470-2045(16)00138-8] [PMID: 26922857]
[http://dx.doi.org/10.1038/bjc.2017.478] [PMID: 29438373]
[http://dx.doi.org/10.1002/cam4.3771] [PMID: 33586360]
[http://dx.doi.org/10.1158/1078-0432.CCR-10-3409] [PMID: 21712450]
[http://dx.doi.org/10.1002/cncr.33626] [PMID: 34043812]
[http://dx.doi.org/10.1186/s13045-016-0332-8] [PMID: 27716285]
[http://dx.doi.org/10.1200/JCO.22.02328] [PMID: 36521102]
[http://dx.doi.org/10.1038/s41591-021-01444-0] [PMID: 34341578]
[http://dx.doi.org/10.1111/1759-7714.13386] [PMID: 32163662]
[http://dx.doi.org/10.1200/JCO.2015.63.5995] [PMID: 26884585]
[PMID: 12171890]
[http://dx.doi.org/10.1016/j.virusres.2005.07.010] [PMID: 16139912]
[http://dx.doi.org/10.1038/nrd1381] [PMID: 15136787]
[http://dx.doi.org/10.1200/JCO.2005.06.081] [PMID: 15585754]
[http://dx.doi.org/10.18632/oncotarget.17264] [PMID: 28881773]
[http://dx.doi.org/10.1016/j.gene.2018.02.026] [PMID: 29454091]
[http://dx.doi.org/10.1097/IGC.0000000000001129] [PMID: 28953502]
[http://dx.doi.org/10.1001/jamaoncol.2018.3039] [PMID: 30098152]
[http://dx.doi.org/10.1007/s10637-020-00925-2] [PMID: 32363427]
[http://dx.doi.org/10.3892/ol.2020.11685] [PMID: 32724339]
[http://dx.doi.org/10.1038/s41419-020-2511-3] [PMID: 32366856]
[http://dx.doi.org/10.1158/1078-0432.CCR-21-2241] [PMID: 34844980]
[http://dx.doi.org/10.1016/j.annonc.2020.08.1044]
[http://dx.doi.org/10.1002/onco.13857] [PMID: 34105207]
[http://dx.doi.org/10.1158/1078-0432.CCR-20-2950] [PMID: 33832949]
![Wayfinder Image](/images/wayfinder.jpg)